var data={"title":"Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/contributors\" class=\"contributor contributor_credentials\">Philip J Podrid, MD, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/contributors\" class=\"contributor contributor_credentials\">Wilson S Colucci, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/contributors\" class=\"contributor contributor_credentials\">Brian Olshansky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/contributors\" class=\"contributor contributor_credentials\">Brian C Downey, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both atrial and ventricular arrhythmias are common in patients with heart failure (HF) and cardiomyopathy, regardless of underlying etiology [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/1\" class=\"abstract_t\">1</a>]. They can cause symptoms, morbidity (such as stroke due to embolization with atrial fibrillation), and may be responsible for sudden cardiac death (SCD).</p><p>The pathogenesis of ventricular arrhythmias in patients with HF and cardiomyopathy will be reviewed here. The indications for and methods of treatment of ventricular arrhythmias and of atrial fibrillation in these patients are discussed separately. (See <a href=\"topic.htm?path=ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy\" class=\"medical medical_review\">&quot;Ventricular arrhythmias in heart failure and cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=the-management-of-atrial-fibrillation-in-patients-with-heart-failure\" class=\"medical medical_review\">&quot;The management of atrial fibrillation in patients with heart failure&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are multiple factors responsible for the frequency of ventricular arrhythmias in patients with heart failure (HF) and cardiomyopathy. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Underlying structural disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mechanical factors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neurohormonal factors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Electrolyte abnormalities</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ischemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Underlying structural disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extensive myocardial damage and fibrosis or the loss of cell-to-cell coupling in patients with dilated cardiomyopathy provides the proper substrate for reentry, the mechanism thought to be responsible for most ventricular arrhythmias. In the cardiomyopathic heart, for example, new reentrant wave fronts may be initiated by epicardial breakthrough of the impulse followed by a line of conduction block parallel to the epicardial fiber orientation, suggesting the importance of increased fibrosis and the resulting increase in tissue anisotropy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=reentry-and-the-development-of-cardiac-arrhythmias\" class=\"medical medical_review\">&quot;Reentry and the development of cardiac arrhythmias&quot;</a>.)</p><p>A focal mechanism may also contribute to ventricular arrhythmia in patients with a nonischemic cardiomyopathy. This possibility was demonstrated in a study in which three-dimensional intraoperative mapping for intramural sites was performed in six patients undergoing cardiac transplantation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/3\" class=\"abstract_t\">3</a>]. Spontaneous or induced ventricular arrhythmia arose primarily in the subendocardium by a focal mechanism, probably from triggered activity arising from either early afterdepolarizations or delayed afterdepolarizations, without evidence of reentry. Although there was evidence of conduction delay and block, these sites were consistently distant from the sites of focal initiation.</p><p>Myocardial repolarization is altered in congestive heart failure, independent of the etiology of the cardiomyopathy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/4\" class=\"abstract_t\">4</a>]. This is the result of downregulation of the calcium-independent transient outward potassium current and inward rectifier potassium current [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/5\" class=\"abstract_t\">5</a>]. The Kv4.3 gene encodes all or part of the outward potassium current; in one series of patients with heart failure, altered transcription of this gene and the ensuing reduction in mRNA were responsible for the decline in the outward potassium current [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/6\" class=\"abstract_t\">6</a>]. Another mechanism for altered repolarization is a late sodium current, found in high density in cardiomyocytes of animals with chronic heart failure; this current is characterized by an ultraslow, voltage-independent inactivation and reactivation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/7\" class=\"abstract_t\">7</a>].</p><p>The surface electrocardiogram (ECG) may show increased QT dispersion, indicative of spatial heterogeneity in repolarization [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/8\" class=\"abstract_t\">8</a>]. Temporal variations in repolarization, manifest as beat to beat fluctuation in the <span class=\"nowrap\">QT/QTc</span> intervals, have also been observed; the variability increases with worsening functional class [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/9\" class=\"abstract_t\">9</a>]. The abnormalities in repolarization may be associated with a potential for polymorphic ventricular tachycardia and ventricular fibrillation.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Mechanical factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mechanical factors which can alter the electrophysiologic properties (electromechanical feedback) of myocardial tissue in HF include an increase in wall stress and left ventricular dilation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/10,11\" class=\"abstract_t\">10,11</a>]. In the normal heart, acute myocardial stretch does not alter transverse or longitudinal conduction velocity but shortens the action potential duration and the membrane refractory period, while increasing spontaneous automaticity and triggered activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/12\" class=\"abstract_t\">12</a>]. These effects are more pronounced at faster heart rates. One animal model found that these electrophysiologic changes are mediated by activation of the beta adrenergic receptor and an increase in cyclic AMP-mediated potassium currents [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/13\" class=\"abstract_t\">13</a>]. In contrast, an animal model of dilated cardiomyopathy noted significant prolongation of refractoriness and action potential duration without a change in conduction times [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/14\" class=\"abstract_t\">14</a>]. Additional volume loading resulted in further prolongation of these parameters; volume unloading with <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a> did not normalize them.</p><p>Since regions of the heart differ in mechanical function, electromechanical feedback may result in an increase in dispersion of action potential duration and membrane recovery. In addition, electromechanical feedback decreases in magnitude as steady state heart rate increases [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/15\" class=\"abstract_t\">15</a>]. These observations have implications in the setting of frequent ventricular premature beats, since the occurrence of short and long intervals from beat to beat may enhance dispersion of recovery.</p><p>These effects can increase the incidence of arrhythmias. Among 311 patients in the SOLVD (Studies of Left Ventricular Dysfunction) trial, for example, there was a direct correlation between left ventricular end-diastolic volume and the prevalence of ventricular arrhythmia&nbsp;[<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Neurohormonal factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Heart failure results in the activation of the sympathetic nervous and renin-angiotensin systems in an attempt to preserve homeostasis in the face of decreased cardiac output [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Markers for sympathetic activation and withdrawal of parasympathetic tone include heart rate, which is increased in HF; heart rate variability, which is reduced [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/19\" class=\"abstract_t\">19</a>]; and baroreceptor sensitivity, which is depressed [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/20\" class=\"abstract_t\">20</a>]. (See <a href=\"topic.htm?path=pathophysiology-of-heart-failure-neurohumoral-adaptations\" class=\"medical medical_review\">&quot;Pathophysiology of heart failure: Neurohumoral adaptations&quot;</a>.)</p><p>One study of 142 patients with HF found that depressed baroreceptor receptor sensitivity, but not heart rate variability, was associated with the presence of nonsustained ventricular tachycardia (odds ratio 3.8) and, in the presence of high pulmonary capillary wedge pressure (an indirect index of left ventricular stretch or wall stress), the odds ratio for nonsustained ventricular tachycardia increased to 6.5 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/20\" class=\"abstract_t\">20</a>]. This observation suggests a synergistic effect of autonomic system imbalance and left ventricular stretch in predisposing to ventricular arrhythmia.</p><p>Neurohumoral activation can promote arrhythmia formation via a variety of mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Catecholamines are arrhythmogenic by virtue of their ability to enhance automaticity, precipitate triggered activity, and alter conduction and refractoriness, which may promote reentry.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Angiotensin II can indirectly promote arrhythmia formation via low potassium or magnesium levels, resulting from potassium and magnesium loss in the urine. It can also potentiate the effects of the sympathetic nervous system through central or peripheral actions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both systems may be arrhythmogenic because the associated vasoconstriction alters loading conditions, affecting wall stress and mechanical factors as described above.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic dilated cardiomyopathy may be associated with a nonhomogeneous distribution of sympathetic fibers; regions with necrosis and dense scar show myocardial denervation, similar to what has been observed after an acute myocardial infarction (MI) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/21\" class=\"abstract_t\">21</a>]. This, in turn, may lead to denervation hypersensitivity with increased sensitivity to circulating catecholamines.</p><p/><p>In contrast, other regions of the myocardium may show an increase in sympathetic innervation, possibly the result of injury-related nerve sprouting. Immunocytochemical staining of tissue from patients with severe heart failure that was due to either an idiopathic cardiomyopathy or an MI found regional hyperinnervation, with an increase in sympathetic nerve fibers in the perivascular regions and the periphery of injured myocardium, among those with a history of ventricular tachycardia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Autoantibodies against beta adrenergic receptors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoantibodies against beta-1 adrenergic receptors can be detected in up to 50 percent of patients with an idiopathic dilated cardiomyopathy. One subgroup of autoantibodies, directed against the second extracellular domain of the beta-1 adrenergic receptor, exerts sympathomimetic activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/23\" class=\"abstract_t\">23</a>]. In a report of 104 patients, these autoantibodies were detected in 38 percent of patients and were closely associated with serious ventricular arrhythmias and were independent predictors of sudden death [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=causes-of-dilated-cardiomyopathy#H27\" class=\"medical medical_review\">&quot;Causes of dilated cardiomyopathy&quot;, section on 'Autoimmunity'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Electrolyte abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HF often have electrolyte abnormalities, particularly diuretic-induced hypokalemia and hypomagnesemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/25\" class=\"abstract_t\">25</a>]. In addition, stimulation of beta-2 receptors by circulating epinephrine can transiently lower the plasma potassium concentration by enhancing potassium entry into cells. (See <a href=\"topic.htm?path=causes-of-hypokalemia-in-adults#H17666854\" class=\"medical medical_review\">&quot;Causes of hypokalemia in adults&quot;, section on 'Elevated beta-adrenergic activity'</a>.)</p><p>Hypokalemia and possibly hypomagnesemia may be directly arrhythmogenic. In the SOLVD trial, for example, non-potassium-sparing diuretic use at baseline was associated with a lower serum concentration of potassium and a higher incidence of arrhythmic death compared with no diuretic use (3.1 versus 1.7 deaths per 100 patient-years) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/26\" class=\"abstract_t\">26</a>]. This relationship remained significant after controlling for other factors (relative risk 1.33) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/26\" class=\"abstract_t\">26</a>]. Low myocardial cell magnesium concentrations can contribute to abnormal repolarization [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/27\" class=\"abstract_t\">27</a>] and low potassium and magnesium may also potentiate the arrhythmogenic effects of catecholamines, digitalis, or antiarrhythmic agents. (See <a href=\"topic.htm?path=use-of-diuretics-in-patients-with-heart-failure\" class=\"medical medical_review\">&quot;Use of diuretics in patients with heart failure&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whether silent or overt, ischemia, through its effects on electrolyte shifts, acidosis, heterogeneity of electrophysiologic properties, and other mediators, may lead to alteration in the electrophysiologic milieu, including regional alterations in conduction and refractoriness and enhanced automaticity. These alterations may be enhanced by hypokalemia, increased catecholamine levels, digitalis, and antiarrhythmic agents.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Role in sudden death</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although sudden death is most often the result of a ventricular tachyarrhythmia, the role of an acute coronary event in patients with heart failure is uncertain (see <a href=\"topic.htm?path=pathophysiology-and-etiology-of-sudden-cardiac-arrest\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of sudden cardiac arrest&quot;</a>). The prevalence of an acute coronary finding (coronary thrombus, ruptured plaque, or MI) and its relationship to sudden cardiac death (SCD) was examined in one autopsy study of 171 patients with heart failure [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/28\" class=\"abstract_t\">28</a>]. In patients with significant coronary artery disease, an acute coronary finding was found in 54 percent who died suddenly and in 32 percent who died of myocardial failure, although an acute coronary event had not been clinically diagnosed before death. In contrast, an acute coronary finding was uncommon in those without coronary disease, present in 5 percent of those who died suddenly and 10 percent of those who died from myocardial failure.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The drugs used to treat heart failure (HF) can directly or indirectly precipitate arrhythmia formation. The role of diuretic-induced electrolyte disturbances has already been discussed.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Phosphodiesterase inhibitors &ndash; Phosphodiesterase inhibitors are positive inotropic agents that are not currently used in the management of HF (see <a href=\"topic.htm?path=inotropic-agents-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Inotropic agents in heart failure with reduced ejection fraction&quot;</a>). These drugs increase intracellular calcium, which can increase cyclic AMP and precipitate afterdepolarizations, resulting in triggered activity. They can also exacerbate ventricular arrhythmias by inducing ischemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/29\" class=\"abstract_t\">29</a>]. A number of trials have shown that one such agent, <a href=\"topic.htm?path=milrinone-drug-information\" class=\"drug drug_general\">milrinone</a>, increased the frequency of all forms of spontaneous arrhythmia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/30-32\" class=\"abstract_t\">30-32</a>] and, in a long-term survival trial (PROMISE), was associated with a 20 percent excess in mortality compared with placebo [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sympathomimetic drugs &ndash; Studies with the sympathomimetic agents (eg, <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a>, <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>) have shown an increased frequency of ventricular arrhythmias <span class=\"nowrap\">and/or</span> increased mortality [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/34\" class=\"abstract_t\">34</a>].<br/><br/>The use of sympathomimetic drugs is also associated with an increased incidence of hospitalization for arrhythmia, especially atrial fibrillation, ventricular tachycardia, and ventricular fibrillation. In one study of 149 patients with heart failure who were admitted for arrhythmia, 22 percent were receiving an inhaled or systemic sympathomimetic (<a href=\"topic.htm?path=terbutaline-drug-information\" class=\"drug drug_general\">terbutaline</a> or albuterol) compared with their use in 11 percent of matched control patients not admitted for arrhythmia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/35\" class=\"abstract_t\">35</a>]. The use of any sympathomimetic drug was associated with an increased risk of admission for arrhythmia (adjusted odds ratio 4.0), while the adjusted odds ratio was 15.7 for the use of a systemic sympathomimetic agent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">Digoxin</a> &ndash; There have been conflicting data on the effect of digoxin on the frequency and clinical significance of arrhythmias in HF. Two relatively large and well done studies found that digoxin did not significantly affect the frequency of ventricular arrhythmias in patients with congestive heart failure [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/32,36\" class=\"abstract_t\">32,36</a>]. On the other hand, two retrospective studies in patients with HF after acute MI reported an excess mortality in patients who had complex ventricular arrhythmias who were treated with digitalis&nbsp;[<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/37,38\" class=\"abstract_t\">37,38</a>]; however, other reports did not confirm this increase in risk in post-MI patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/39,40\" class=\"abstract_t\">39,40</a>].<br/><br/>The largest trial evaluating the efficacy of digoxin in HF, the DIG trial, randomly assigned approximately 6800 patients with HF to digoxin or placebo; all patients were also treated with an angiotensin-converting enzyme (ACE) inhibitor and, if necessary, a diuretic [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/41\" class=\"abstract_t\">41</a>]. Digoxin was associated with an increase in non-HF cardiac mortality that included a trend towards increased mortality from arrhythmia. This trend counterbalanced the fewer deaths from progressive heart failure in patients treated with digoxin, leading to no effect on overall patient survival. (See <a href=\"topic.htm?path=use-of-digoxin-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of digoxin in heart failure with reduced ejection fraction&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2333374\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both atrial and ventricular arrhythmias are common in patients with heart failure (HF) and cardiomyopathy and can contribute to symptoms, morbidity, and mortality. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extensive myocardial damage and fibrosis or the loss of cell-to-cell coupling in patients with dilated cardiomyopathy provides the proper substrate for reentry, the mechanism thought to be responsible for most ventricular arrhythmias in persons with HF. (See <a href=\"#H3\" class=\"local\">'Underlying structural disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mechanical factors which can alter the electrophysiologic properties (electromechanical feedback) of myocardial tissue in HF include an increase in wall stress and left ventricular dilation. (See <a href=\"#H4\" class=\"local\">'Mechanical factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neurohumoral activation can promote arrhythmia formation via a variety of mechanisms, including enhanced automaticity, electrolyte disturbances, vasoconstriction, and fibrosis. (See <a href=\"#H5\" class=\"local\">'Neurohormonal factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with HF often have electrolyte abnormalities, particularly diuretic-induced hypokalemia and hypomagnesemia, which may be directly arrhythmogenic. (See <a href=\"#H7\" class=\"local\">'Electrolyte abnormalities'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some of the medications used to treat HF, such as phosphodiesterase inhibitors, sympathomimetic agents, and <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a>, may directly or indirectly precipitate arrhythmia formation. (See <a href=\"#H10\" class=\"local\">'Drugs'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/1\" class=\"nounderline abstract_t\">Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986; 57:3B.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/2\" class=\"nounderline abstract_t\">Wu TJ, Ong JJ, Hwang C, et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 1998; 32:187.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/3\" class=\"nounderline abstract_t\">Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98:2404.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/4\" class=\"nounderline abstract_t\">Tomaselli GF, Beuckelmann DJ, Calkins HG, et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994; 90:2534.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/5\" class=\"nounderline abstract_t\">Beuckelmann DJ, N&auml;bauer M, Erdmann E. Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993; 73:379.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/6\" class=\"nounderline abstract_t\">K&auml;&auml;b S, Dixon J, Duc J, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998; 98:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/7\" class=\"nounderline abstract_t\">Maltsev VA, Sabbah HN, Higgins RS, et al. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998; 98:2545.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/8\" class=\"nounderline abstract_t\">Grimm W, Steder U, Menz V, et al. QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 78:458.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/9\" class=\"nounderline abstract_t\">Berger RD, Kasper EK, Baughman KL, et al. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997; 96:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/10\" class=\"nounderline abstract_t\">White CW, Mirro MJ, Lund DD, et al. Alterations in ventricular excitability in conscious dogs during development of chronic heart failure. Am J Physiol 1986; 250:H1022.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/11\" class=\"nounderline abstract_t\">Dean JW, Lab MJ. Arrhythmia in heart failure: role of mechanically induced changes in electrophysiology. Lancet 1989; 1:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/12\" class=\"nounderline abstract_t\">Reiter MJ, Landers M, Zetelaki Z, et al. Electrophysiological effects of acute dilatation in the isolated rabbit heart: cycle length-dependent effects on ventricular refractoriness and conduction velocity. Circulation 1997; 96:4050.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/13\" class=\"nounderline abstract_t\">Lerman BB, Engelstein ED, Burkhoff D. Mechanoelectrical feedback: role of beta-adrenergic receptor activation in mediating load-dependent shortening of ventricular action potential and refractoriness. Circulation 2001; 104:486.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/14\" class=\"nounderline abstract_t\">Zhu WX, Johnson SB, Brandt R, et al. Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. J Am Coll Cardiol 1997; 30:825.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/15\" class=\"nounderline abstract_t\">Horner SM, Dick DJ, Murphy CF, Lab MJ. Cycle length dependence of the electrophysiological effects of increased load on the myocardium. Circulation 1996; 94:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/16\" class=\"nounderline abstract_t\">Koilpillai C, Qui&ntilde;ones MA, Greenberg B, et al. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol 1996; 77:606.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/17\" class=\"nounderline abstract_t\">Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988; 62:25A.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/18\" class=\"nounderline abstract_t\">Packer M, Gottlieb SS, Blum MA. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med 1987; 82:4.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/19\" class=\"nounderline abstract_t\">Casolo G, Balli E, Taddei T, et al. Decreased spontaneous heart rate variability in congestive heart failure. Am J Cardiol 1989; 64:1162.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/20\" class=\"nounderline abstract_t\">Mortara A, La Rovere MT, Pinna GD, et al. Depressed arterial baroreflex sensitivity and not reduced heart rate variability identifies patients with chronic heart failure and nonsustained ventricular tachycardia: the effect of high ventricular filling pressure. Am Heart J 1997; 134:879.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/21\" class=\"nounderline abstract_t\">Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/22\" class=\"nounderline abstract_t\">Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000; 101:1960.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/23\" class=\"nounderline abstract_t\">Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103:1765.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/24\" class=\"nounderline abstract_t\">Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:418.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/25\" class=\"nounderline abstract_t\">Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990; 16:827.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/26\" class=\"nounderline abstract_t\">Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/27\" class=\"nounderline abstract_t\">Haigney MC, Wei S, K&auml;&auml;b S, et al. Loss of cardiac magnesium in experimental heart failure prolongs and destabilizes repolarization in dogs. J Am Coll Cardiol 1998; 31:701.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/28\" class=\"nounderline abstract_t\">Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102:611.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/29\" class=\"nounderline abstract_t\">Stambler BS, Wood MA, Ellenbogen KA. Sudden death in patients with congestive heart failure: future directions. Pacing Clin Electrophysiol 1992; 15:451.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/30\" class=\"nounderline abstract_t\">Holmes JR, Kubo SH, Cody RJ, Kligfield P. Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. Am Heart J 1985; 110:800.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/31\" class=\"nounderline abstract_t\">Anderson JL, Askins JC, Gilbert EM, et al. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J 1986; 111:466.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/32\" class=\"nounderline abstract_t\">DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320:677.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/33\" class=\"nounderline abstract_t\">Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/34\" class=\"nounderline abstract_t\">Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986; 74(Suppl II):II.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/35\" class=\"nounderline abstract_t\">Bouvy ML, Heerdink ER, De Bruin ML, et al. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000; 160:2477.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/36\" class=\"nounderline abstract_t\">Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989; 14:564.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/37\" class=\"nounderline abstract_t\">Moss AJ, Davis HT, Conard DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981; 64:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/38\" class=\"nounderline abstract_t\">Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55:623.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/39\" class=\"nounderline abstract_t\">Ryan TJ, Bailey KR, McCabe CH, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS). Circulation 1983; 67:735.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/40\" class=\"nounderline abstract_t\">Muller JE, Turi ZG, Stone PH, et al. Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. N Engl J Med 1986; 314:265.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy/abstract/41\" class=\"nounderline abstract_t\">Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3453 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2333374\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Underlying structural disease</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Mechanical factors</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Neurohormonal factors</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Autoantibodies against beta adrenergic receptors</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Electrolyte abnormalities</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Ischemia</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Role in sudden death</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">Drugs</a></li></ul></li><li><a href=\"#H2333374\" id=\"outline-link-H2333374\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-dilated-cardiomyopathy\" class=\"medical medical_review\">Causes of dilated cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hypokalemia-in-adults\" class=\"medical medical_review\">Causes of hypokalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inotropic-agents-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Inotropic agents in heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-sudden-cardiac-arrest\" class=\"medical medical_review\">Pathophysiology and etiology of sudden cardiac arrest</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-heart-failure-neurohumoral-adaptations\" class=\"medical medical_review\">Pathophysiology of heart failure: Neurohumoral adaptations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reentry-and-the-development-of-cardiac-arrhythmias\" class=\"medical medical_review\">Reentry and the development of cardiac arrhythmias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-management-of-atrial-fibrillation-in-patients-with-heart-failure\" class=\"medical medical_review\">The management of atrial fibrillation in patients with heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-digoxin-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of digoxin in heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-diuretics-in-patients-with-heart-failure\" class=\"medical medical_review\">Use of diuretics in patients with heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ventricular-arrhythmias-in-heart-failure-and-cardiomyopathy\" class=\"medical medical_review\">Ventricular arrhythmias in heart failure and cardiomyopathy</a></li></ul></div></div>","javascript":null}